Use of intravenous brivaracetam in status epilepticus: A multicenter registry
Abstract
Objective: The pharmacokinetics of brivaracetam (BRV), added to its effectiveness observed in animal models of status epilepticus (SE), makes this drug attractive for use in emergency situations. Our objective was to evaluate the use of intravenous BRV in a multicenter study.Methods: A retrospective multicenter registry of SE cases treated with BRV was created. These patients were evaluated between January and December 2018 at seven hospitals in Spain. Demographic variables, SE characteristics, concomitant drugs, loading doses, and response to treatment were collected.Results: Forty‐three patients were registered. The mean age was 56 ± 23.1 years, 51.2% were male, 29 had previous epilepsy, 24 (55.8%) had prominent motor symptoms, and 19 had nonconvulsive symptoms. Regarding the etiology, 19 (44.2%) were considered acute symptomatic, 16 (17.2%) remote symptomatic, four (9.3%) progressive symptomatic, and four (9.3%) cryptogenic. Regarding concomitant antiepileptic drugs (AEDs), 17 had previously received levetiracetam (LEV). In 14 patients, BRV was used early (first or second AED). The median loading dose was 100 mg (range = 50‐400), and the weight‐adjusted dose was 1.8 mg/kg (range = 0.4‐7.3). BRV was effective in 54% (n = 23), and a response was observed in P = 0.09), but there were no differences regarding SE type and the concomitant use of LEV. In those with the fastest responses, we observed that both the total administered dose (300 mg vs 100 mg, P = 0.008) and the weight‐adjusted dose (3.85 mg vs 1.43 mg, P = 0.006) were significantly higher. The receiver operating characteristic curve showed that the best cutoff point for a faster response was 1.82 mg/kg.Significance: BRV is useful for the treatment of SE, even when patients are already being treated with LEV. The response rate seems higher when it is administered earlier and at higher doses (>1.82 mg/kg).Keywords
This publication has 15 references indexed in Scilit:
- Intravenous brivaracetam in status epilepticus: Correlation between loading dose, plasma levels and clinical responseEpilepsy Research, 2019
- Intravenous brivaracetam in status epilepticus: A retrospective single‐center studyEpilepsia, 2018
- Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticusEpilepsia, 2018
- Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticusEpilepsia, 2017
- Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitalsEpilepsy & Behavior, 2017
- Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionEpilepsia, 2015
- A definition and classification of status epilepticus – Report of theILAETask Force on Classification of Status EpilepticusEpilepsia, 2015
- Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant propertiesEuropean Journal of Pharmacology, 2011
- Status Epilepticus Severity Score (STESS)Journal of Neurology, 2008
- Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2ABritish Journal of Pharmacology, 2008